孟加拉国内分泌学会(BES)关于COVID-19患者糖尿病及其他内分泌疾病管理的立场声明
该立场声明由孟加拉国内分泌学会制定,针对COVID-19合并糖尿病及其他内分泌疾病患者,提出适用于初级和专科诊疗的实用建议。声明指出糖尿病患者COVID-19致死风险可比非糖尿病者高至多50%,合并糖尿病与COVID-19者病死率(CFR)为7.3–9.2%,而无合并症者为0.9–1.4%。糖尿病酮症酸中毒可能是COVID-19死亡原因之一,患者血糖波动大,可能与饮食不规律、运动减少、糖皮质激素分泌增加及使用糖皮质激素有关。声明强调多数患者HbA1c目标<7.0%但可适当放宽,更重视日常血糖水平,必须避免低血糖(<3.9 mmol/l),重症患者需频繁监测血糖。
要点
- 糖尿病患者COVID-19致死风险可比非糖尿病者高至多50%;合并糖尿病与COVID-19者CFR 7.3–9.2%,无合并症者0.9–1.4%。
- 糖尿病酮症酸中毒可能是COVID-19死亡原因之一,需警惕。
- COVID-19糖尿病患者血糖波动大,可能与饮食不规律、运动减少、糖皮质激素分泌增加及使用糖皮质激素有关。
- 多数患者HbA1c目标<7.0%,适当临床情况可放宽;更重视日常血糖水平,必须避免低血糖(<3.9 mmol/l)。
- 重症患者需频繁监测血糖。
适用人群与场景
- COVID-19合并糖尿病或其他内分泌疾病或任何其他合并症的患者,适用于初级和专科诊疗场景。
- 重点关注老年人和有合并症等脆弱人群。
诊断标准与关键阈值
- HbA1c目标:多数患者<7.0%,适当临床情况可放宽。
- 低血糖阈值:血糖<3.9 mmol/l必须避免。
处置流程与药物剂量
- 更重视日常血糖水平而非仅HbA1c。
- 重症患者需频繁监测血糖。
红旗征与不能漏的情况
- 糖尿病酮症酸中毒可能是COVID-19死亡原因之一,需警惕。
研究设计与关键结果
- 制定机构:孟加拉国内分泌学会(Bangladesh Endocrine Society)。
- 方法:形成适用于初级和专科诊疗的实用建议。
证据类型、等级与局限
- 证据类型:立场声明(指南/共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对COVID-19合并糖尿病患者,应设定个体化HbA1c目标(多数<7.0%,适当临床情况可放宽),并重点管理日常血糖、避免低血糖(<3.9 mmol/l)。
- 重症患者需频繁监测血糖。
指南或共识出处
- 孟加拉国内分泌学会(Bangladesh Endocrine Society)立场声明,发表于Diabetes Metab Syndr Obes。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The year 2020 witnessed a largely unprecedented pandemic of coronavirus disease (COVID-19), caused by SARS COV-2. Many people with COVID-19 have comorbidities, including diabetes, hypertension and cardiovascular diseases, which are significantly associated with worse outcomes. Moreover, COVID-19 itself is allied with deteriorating hyperglycemia. Therefore, Bangladesh Endocrine Society has formulated some practical recommendations for management of diabetes and other endocrine diseases in patients with COVID-19 for use in both primary and specialist care settings.
OBJECTIVE: The objective of the article is to develop a guideline to protect the vulnerable group with utmost preference - the elderly and those with comorbid conditions. Therefore, to ensure the adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.
CONSIDERING AND MONITORING ISSUES: The risk of a fatal outcome from COVID-19 may be up to 50% higher in patients with diabetes than in non-diabetics.Patients with diabetes and COVID had CFR 7.3-9.2%, compared with 0.9-1.4% in patients without comorbidities.Diabetic ketoacidosis may be one of the causes of mortality in COVID-19.There is wide fluctuation of blood glucose in these patients, probably due to irregular diet, reduced exercise, increased glucocorticoids secretion, and use of glucocorticoids. HbA1c should be <7.0% for the majority of the patients, this target may be relaxed in appropriate clinical settings.More emphasis should be given on day-to-day blood glucose levels. Hypoglycemia (<3.9 mmol/l) must be avoided.Frequent monitoring of blood glucose is needed in critically ill patients.
CONCLUSION: The fight against COVID-19 has been proven to be a challenging one. Therefore, all healthcare personnel should make the best use of updated knowledge and skills to ensure adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.
参考来源
- Pathan F, Selim S, Fariduddin M, et al. Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19. Diabetes Metab Syndr Obes. 2021. PMID: 34040407. doi:10.2147/DMSO.S293688
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。